Logo for the journal Current Trends in Medicine and Clinical Research (CTMCR). Current Trends in Medicine and Clinical Research (CTMCR), also known as Current Trends in Medicine Journal, Trends in Medicine and Clinical Research

Systemic Light-Chain Amyloidosis: Evolving Diagnostic Paradigms and Emerging Therapeutic Strategies Beyond ANDROMEDA 

Authors
  • Parikshit Nagda

    Janardhan rai nagar university

    Author

  • Udai bhan Singh Rathore

    Author

  • Ghisaram Dewasi

    Author

Keywords:
AL amyloidosis; systemic amyloidosis; daratumumab; ANDROMEDA; plasma cell dyscrasia; light chain; cardiac amyloidosis; amyloid fibril; CAR-T therapy; bispecific antibody; venetoclax; autologous stem cell transplantation; minimal residual disease; proteasome inhibitor; organ response
Abstract

Background: Systemic light-chain (AL) amyloidosis is a clonal plasma-cell disorder whose prognosis hinges on early diagnosis and rapid deepening of haematologic response. The ANDROMEDA trial established daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (CyBorD) as a new standard of first-line care, yet diagnostic delays persist and relapsed/refractory disease remains therapeutically challenging. This systematic review and meta-analysis synthesizes evolving diagnostic paradigms and evaluates emerging therapeutic strategies beyond ANDROMEDA.

Methods: This review was conducted per PRISMA 2020. Randomized trials, cohort studies, and case series (n ≥ 10) reporting on diagnostic modalities or therapies for AL amyloidosis in adults were eligible. Two independent reviewers performed screening, data extraction, and risk-of-bias assessment (RoB 2, ROBINS-I). Random-effects meta-analysis pooled [complete haematologic response (CHR), organ response, overall survival (OS), and grade ≥ 3 adverse events]; heterogeneity was evaluated with I², and certainty appraised with GRADE.

Result and Conclusions: Diagnostic innovation is central to improving outcomes in AL amyloidosis, and post-ANDROMEDA strategies show promising efficacy and acceptable safety. Standardization of response criteria and prospective comparative data are needed. These findings support a biomarker-guided, risk-adapted therapeutic framework.

Downloads
Published
30-10-2026
Section
Review Articles
License

Copyright (c) 2026 Parikshit Nagda, Udai bhan Singh Rathore, Ghisaram Dewasi (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Systemic Light-Chain Amyloidosis: Evolving Diagnostic Paradigms and Emerging Therapeutic Strategies Beyond ANDROMEDA . (2026). Current Trends in Medicine and Clinical Research, 5(4). https://doi.org/10.5281/zenodo.23790867

Most read articles by the same author(s)